Sung Won Choi

TL;DR: Cox regression analysis revealed that the biomarker panel predicted survival independently of GVHD severity, and a panel of 4 biomarkers can confirm the diagnosis ofGVHD in patients at onset of clinical symptoms of GVsHD and provide prognostic information independent of GvHD severity.

TL;DR: ST2 levels measured at the initiation of therapy for GV HD and during the first month after transplantation improved risk stratification for treatment-resistant GVHD and death without relapse after transplanting.

TL;DR: Elafin has significant diagnostic and prognostic value as a biomarker of skin GVHD and is validated with enzyme-linked immunosorbent assay in samples from 492 patients, showing that elafin concentrations may serve as a noninvasive diagnostic test as well as a prognostic marker in determining GV HD grading in the clinic.

TL;DR: The clinical evidence for emerging approaches in the prevention of GVHD is assessed, including therapies targeting T cells or B cells, the use of mesenchymal stem cells, chemo-cytokine antagonists, and theUse of novel molecular regulators that target multiple cell types simultaneously, including atorvastatin, bortezomib, and epigenetic modulators.

TL;DR: Etanercept plus steroids as initial therapy for acute GVHD results in a substantial majority of CRs, and patients treated with etanercept were more likely to achieve CR than those treated with steroids alone.